Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes
Authors:
- Amy R PeckAPAmy R Peck
- Agnieszka K WitkiewiczAWAgnieszka K Witkiewicz
- Chengbao LiuCLChengbao Liu
- Alexander C KlimowiczAKAlexander C Klimowicz
- Ginger A StringerGSGinger A Stringer
- Edward PequignotEPEdward Pequignot
- Boris FreydinBFBoris Freydin
- Ning YangNYNing Yang
- Adam ErtelAEAdam Ertel
- Thai H TranTTThai H Tran
- Melanie A GirondoMGMelanie A Girondo
- Anne L RosenbergARAnne L Rosenberg
Open Access
- 4 October 2012
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (5) , R130
Abstract
Introduction: Signal transducer and activator of transcripton-5a (Stat5a) and its close homologue, Stat5b, mediate key physiological effects of prolactin and growth hormone in mammary glands. In breast cancer, loss of nuclear localized and tyrosine phosphorylated Stat5a/b is associated with poor prognosis and increased risk of antiestrogen therapy failure. Here we quantify for the first time levels of Stat5a and Stat5b over breast cancer progression, and explore their potential association with clinical outcome. Methods: Stat5a and Stat5b protein levels were quantified in situ in breast-cancer progression material. Stat5a and Stat5b transcript levels in breast cancer were correlated with clinical outcome in 936 patients. Stat5a protein was further quantified in four archival cohorts totaling 686 patients with clinical outcome data by using multivariate models. Results: Protein levels of Stat5a but not Stat5b were reduced in primary breast cancer and lymph node metastases compared with normal epithelia. Low tumor levels of Stat5a but not Stat5b mRNA were associated with poor prognosis. Experimentally, only limited overlap between Stat5a- and Stat5b-modulated genes was found. In two cohorts of therapy-naïve, node-negative breast cancer patients, low nuclear Stat5a protein levels were an independent marker of poor prognosis. Multivariate analysis of two cohorts treated with antiestrogen monotherapy revealed that low nuclear Stat5a levels were associated with a more than fourfold risk of unfavorable outcome. Conclusions: Loss of Stat5a represents a new independent marker of poor prognosis in node-negative breast cancer and may be a predictor of response to antiestrogen therapy if validated in randomized clinical trials.Keywords
This publication has 54 references indexed in Scilit:
- Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5Oncogene, 2012
- Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive CellsJournal of Clinical Oncology, 2011
- Mechanisms of Endocrine Resistance in Breast CancerAnnual Review of Medicine, 2011
- Stat5 Promotes Survival of Mammary Epithelial Cells through Transcriptional Activation of a Distinct Promoter in Akt1Molecular and Cellular Biology, 2010
- Prolactin Inhibits BCL6 Expression in Breast Cancer through a Stat5a-Dependent MechanismCancer Research, 2010
- Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancerBreast Cancer Research and Treatment, 2009
- A novel role for signal transducer and activator of transcription 5b (STAT5b) in β1-integrin-mediated human breast cancer cell migrationBreast Cancer Research, 2009
- Dual Roles for NFAT Transcription Factor Genes as Oncogenes and Tumor SuppressorsMolecular and Cellular Biology, 2008
- In vivo identification of novel STAT5 target genesNucleic Acids Research, 2008
- The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancerJournal of Clinical Investigation, 2007